-

Dompé farmaceutici Appoints Shannon K. Sullivan as Chief Commercial Officer Biotech

MILAN, Italy & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé, a leading biopharmaceutical company with operations in Italy and the US, today announced the appointment of Shannon K. Sullivan as Chief Commercial Officer (CCO), effective immediately.

Sullivan is a highly accomplished and respected leader in the biopharmaceutical industry, with over 25 years of experience in general management, sales, commercial operations, marketing, and compliance. She has a proven track record of success in launching and growing new products, driving sales growth, and building high-performing teams.

In her new role, Sullivan will be responsible for leading Dompé's global biotech commercial organization and driving growth across the company's entire portfolio of products. She will also be responsible for developing and executing Dompé's global commercial strategy in the biotech area, and for ensuring that the company has the right products, people, and processes in place to achieve its business goals.

“We are thrilled to welcome Shannon to Dompé as our new Chief Commercial Officer,” said Sergio Dompé, Executive President of Dompé. “Shannon is a world-class leader with a deep understanding of the biopharmaceutical industry and a proven track record of success. We are confident that she will be instrumental in driving growth and innovation at Dompé as we continue to expand our global reach and bring new and innovative medicines to patients around the world.”

Sullivan joins Dompé from Amgen, where she most recently served as Vice President, General Manager of Vasculitis for the Inflammation Business Unit overseeing the TAVNEOS Team. Prior to that, she held a variety of senior roles at Amgen, including Vice President & Managing Director, Amgen, Australia & New Zealand, and Vice President, U.S. Sales, Field Excellence & Capabilities. Sullivan holds a Bachelor of Science in Biotechnology from the University of North Florida and completed post-baccalaureate work at Duquesne University with a concentration in chemistry.

About Dompé

Dompé is a private, rapidly scaling international biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. The R&D department of the company is anchored by EXSCALATE, a structure-based virtual screening platform developed in-house that leverages one of the most powerful supercomputing and artificial intelligence platforms in the world. Today, Dompé employs more than 800 employees worldwide and maintains a US commercial operations hub in the San Francisco Bay Area.

Forward Looking Statements

This press release refers to certain information that may not coincide with expected future results. Dompé firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of indetermination in relation to its research and development activities and the necessary verifications to be performed by regulatory bodies. Therefore, as of today, Dompé cannot guarantee that the expected results will be consistent with the information provided above.

Contacts

Media Contacts - Dompé farmaceutici
Guido Romeo
Director Corporate Communications and Public Affairs
+39 349 4154010
guido.romeo@dompe.com

Dompé farmaceutici


Release Summary
Dompé, a leading biopharmaceutical company with operations in Italy and the US, appointed Shannon K. Sullivan as Chief Commercial Officer (CCO).

Contacts

Media Contacts - Dompé farmaceutici
Guido Romeo
Director Corporate Communications and Public Affairs
+39 349 4154010
guido.romeo@dompe.com

Social Media Profiles
More News From Dompé farmaceutici

From the Eye to the Brain: World’s Top Scientists Gather in Rome to Discuss Future of Neurotrophins in Eye and Brain Research

ROME--(BUSINESS WIRE)--Nature Conferences has convened a meeting of leading global scientists to discuss the state of the art and future lines of research on neurotrophins. The event, From the Eye to the Brain, will focus on the potential new applications of neurotrophins in therapeutic areas including ophthalmology and the central nervous system. The program takes place in Rome June 11-12 and is sponsored by Dompé farmaceutici. Neurotrophins were discovered by Italian Nobel laureate Dr. Rita L...

Dompé Foundation Doubles Its Funding for Rita Levi Montalcini fellowships in Neuroscience and Neurobiology

WASHINGTON--(BUSINESS WIRE)--The Dompé Foundation has announced it doubled to 1 million dollars its support to MA, PhD and post-doc candidates from United States-based universities for 2023. This funding opportunity, which honors the legacy of the only female Italian Nobel laureate in Medicine, is intended for students of any nationality that have already been admitted to a MA, PhD or post-doc program in Neuroscience and Neurobiology at a US university. As with former grants, the Foundation wil...

New Data Reveal Role of SARS-Cov-2 Spike Protein in Covid-19 Associated Coagulopathy

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation1. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COV...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.